Division of Cardiovascular Surgery, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei.
J Vasc Access. 2024 Jan;25(1):125-131. doi: 10.1177/11297298221077605. Epub 2022 May 30.
To report the patency rates after implantation of an interwoven nitinol stent to salvage failing arteriovenous grafts (AVGs) caused by intragraft stenoses.
Between May 2018 and May 2020, 21 Supera stents were placed in 20 patients (18 women; mean age: 79.9 years) who had a failing AVG due to repeat intragraft stenoses. Recurrent AVG dysfunction with same intragraft stenosis within 3 months after first time angioplasty was a criterion for stenting. Those with concurrent treatment for other lesions were excluded.
The technical success rate was 100%. Intragraft stenoses were treated at a median of 19.7 (interquartile range: 6-36) months after graft creation. Access circuit primary patency rates after stent placement were 84% and 35% at 6 and 12 months, respectively. Access circuit secondary patency rates were 100% at 6 and 12 months and 89% at 18 months. Only one patient presented with graft failure due to proximal drainage vein occlusion. The target lesion patency rates were 100% at 6 months and 75% at 12 months. The rate of reintervention for intragraft lesion was 0.15 procedures per year. Stent distortion did not occur under regular cannulation.
The interwoven nitinol stent is a promising treatment for failing AVGs with recurrent intragraft stenoses. The 1-year access circuit primary, secondary, and target lesion patency rates were acceptable, with a low reintervention rate. Stent fracture does not occur in areas of needle puncture.
报告采用编织型镍钛诺支架治疗因腔内狭窄导致的动静脉移植物(AVG)失功的通畅率。
2018 年 5 月至 2020 年 5 月,20 例患者(18 例女性;平均年龄:79.9 岁)因腔内狭窄导致 AVG 失功而接受了 21 枚 Supera 支架置入。AVG 首次血管成形术后 3 个月内出现同一腔内狭窄的复发性 AVG 功能障碍是支架置入的标准。排除同期治疗其他病变的患者。
技术成功率为 100%。腔内狭窄发生在移植物植入后中位时间 19.7(四分位距:6-36)个月。支架置入后,动静脉通路的一期通畅率分别为 6 个月和 12 个月时的 84%和 35%。动静脉通路的二期通畅率分别为 6 个月和 12 个月时的 100%和 18 个月时的 89%。仅 1 例患者因近端引流静脉闭塞而发生移植物失功。靶病变的通畅率分别为 6 个月和 12 个月时的 100%和 75%。腔内病变的再介入率为每年 0.15 次。常规穿刺部位未发生支架变形。
编织型镍钛诺支架是治疗复发性腔内狭窄导致的 AVG 失功的一种有前途的方法。1 年的动静脉通路一期、二期和靶病变通畅率可接受,再介入率低。支架断裂不会发生在穿刺部位。